Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296398 · ClinicalTrials.gov registry record
Long-term Use of Romidepsin in Patients With CTCL
A clinical trial of Cutaneous T Cell Lymphoma, sponsored by Northwestern University.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT02296398 is a study of Cutaneous T Cell Lymphoma that has completed, run by Northwestern University. The registered enrollment target is 47 participants, below the 66-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02296398, a study of Cutaneous T Cell Lymphoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of neoplasm of skin-homing T cells that includes Mycosis Fungoid (MF), which is the most common, Sézary syndrome (SS), the leukemia variant of MF, and other variants of CTCL which are less prevalent. Clinical manifestations and prognosis are highly variable. Improving the management of this incurable disease with limited toxicity is the main point of the current research. Romidepsin is a well-tolerated histone deacetylase inhibitor which has demonstrated activity against advanced stages of CTCL. In November 2009, it was approved by the US Food and Drug Administration (FDA) for the treatment of CTCL in patients who have received at least one prior systemic therapy. FDA-dose approved is 14 mg/m2 days 1, 8, 15 of a 21 day-cycle. It is said that it should be continued as long as the patient receives benefit and tolerates the drug. We experienced in our clinic that a long-term (\>6 months) use of Romidepsin, even with spared doses allows patients to maintain disease in complete remission or under control without severe side effects. We aim to demonstrate how many patients have benefited of this maintenance therapy, and detect the side effects related to the long-term use of Romidepsin, as well as characterize those patients that can get benefit of this therapy.
Conditions Studied
Interventions
- DRUG Romidepsin
Study Locations (1)
Illinois
- Northwestern University Dermatology Department - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296398
The ClinicalTrials.gov registry entry for NCT02296398 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (29% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Romidepsin is the first listed.
NCT02296398 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02296398 about?
NCT02296398 is a clinical study titled "Long-term Use of Romidepsin in Patients With CTCL". Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of neoplasm of skin-homing T cells that includes Mycosis Fungoid (MF), which is the most common, Sézary syndrome (SS), the leukemia variant of MF, and other variants of CTCL which are less prevalent. Clinical manifestations and prognosis ar...
What is the current status of trial NCT02296398?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2015-01. Estimated completion is 2015-08.
What conditions does trial NCT02296398 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma.
What interventions are being tested in trial NCT02296398?
The interventions under investigation include: Romidepsin (DRUG).
Who is sponsoring clinical trial NCT02296398?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296398 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
RECRUITING
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.